A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST) KEAP1/NRF2 and LKB1 Aberrant Tumors

Brief description of study

The purpose of the study is to determine the safety and tolerability of Glutaminase Inhibitor (BeGIN) CB-839 HCl in patients with NF1 mutant malignant peripheral nerve sheath tumors (MPNST), NF1 mutant cancers, KEAP1/NRF2 & STK11/LKB1 pathway aberrant tumors. CB-839 HCl is a potent and selective reversible inhibitor of glutaminase-1 activity. The study drug CB-839 HCl is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.